Abstract 167P
Background
HCC is the most common primary liver malignancy and cause of cancer-related death worldwide and in Bangladesh. It occurs more often in males than females. The incidence of HCC continues to escalate due to HBV, HCV infection, non-alcoholic fatty liver disease (NAFLD). HBV and HCV are also important risk factors for developing chronic liver disease (CLD) and HCC.
Methods
The study was an observational study. All HCC patients in National Institute of Cancer Research and Hospital and Shaheed Suhrawardy Medical College Hospital, Dhaka, Bangladesh from Jan.2010 to Dec.2019 were included. Clinical information and demographic profiles were recorded from departmental documents and retrospectively studied. Patients were arranged as Birch Classification.
Results
Of 1028 patients, 752 (73.15%) were male and 276 (26.85%) were female; M:F was 2.72:1. The average age of HCC onset was 57.9, lowest 23 and highest was 90. The leading age group was ≥60 years, 315 (30.64%) followed by 50-59 year 256 (24.90%), 40-49 year 254 (24.71%). 106 (10.31%) patients presented with metastasis. 688 (66.92%) patients had habitual problems. 478 (46.50%) patients were infected with HBV, 56 (5.45%) were infected with HCV, 632 (61.48%) were suffering from CLD, 180 (17.51%) from NAFLD and only 48 (4.46%) had family histories of malignancy. 240 (23.36%) patients presented with comorbidities. Only 13 (1.26%) were vaccinated against HBV and none had attended for HCC screening. Most patients were poor, 724 (70.43%%) and 683 (66.44%) were illiterate. The leading profession was farmer, 408 (39.69%), followed by housewife, 223 (21.70%).The leading symptom was pain, 348 (33.85%) followed by anorexia, 327 (31.81%), right hypochondriac heaviness, 284 (27.63%). 267 (25.97%) patients presented with impaired liver function, and 339 (32.97%) presented with high alfa feto protein (AFP). 521 (50.68%) patients were on symptomatic treatment prior to attending an oncologist.
Conclusions
HCC is an aggressive cancer and concomitant liver dysfunction with advanced disease impedes curative therapies. HCC can be prevented if appropriate measures are taken, such as HBV vaccination, screening of blood products, use of safe injection practices, treatment and education of alcoholics and drug users.
Clinical trial identification
Editorial acknowledgement
Department of Medical oncology of Shaheed suhrawardy medical college hospital and National Institute of cancer research & hospital
Legal entity responsible for the study
Abdullah Al Mamun Khan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
298P - Abandonment of treatment in teenagers and young adults with cancer: A multi institutional survey
Presenter: B S Ankit
Session: e-Poster Display Session
304P - Identification of nine lncRNAs signature for predicting survival benefit of melanoma patients treated with immune checkpoint inhibitors
Presenter: Jian-Guo Zhou
Session: e-Poster Display Session
305P - Novel co-occurring genomic alterations associated with prediction and prognosis in lung adenocarcinoma
Presenter: Xin Zhao
Session: e-Poster Display Session
306P - Detection of anaplastic lymphoma kinase (ALK) mutations using circulating tumour DNA (ctDNA) in advanced non-squamous non-small cell lung cancer (non-Sq-NSCLC) in Asia
Presenter: Kirsty Lee
Session: e-Poster Display Session
307P - Development of circulating free DNA methylation markers for thyroid nodule diagnostics
Presenter: Shuibing Hong
Session: e-Poster Display Session
308P - The genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumour DNA (ctDNA) in clinical practice
Presenter: Byoung Cho
Session: e-Poster Display Session
309P - Improved diagnostic accuracy in MRI breast lesions using a classification system and multilayer perceptron neural network
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
310P - Genomic biomarker detection in East Asian clinical practice using circulating tumour DNA (ctDNA) from patients with gastrointestinal (GI) tract cancers
Presenter: Sadakatsu Ikeda
Session: e-Poster Display Session
311P - Effect of chemotherapy on fatty liver occurrence in breast and gastrointestinal cancer patients
Presenter: Seyed Alireza Javadinia
Session: e-Poster Display Session
312P - Identification of neoantigen-specific T cell response and anti-tumour immunity in pancreatic cancer
Presenter: Xiaoxiao Du
Session: e-Poster Display Session